The spin-off of Graphene Flagship, INBRAIN Neuroelectronics, had just informed us that it has just received an investment of 1 million from Sabadell Asabys, Alta Life Sciences, ICF and Finaves. This spin-off was born from the Graphene Flagship, partners of the Catalan Institute of Nanoscience and Nanotechnology (ICN2) and ICREA to accelerate the development of new graphene-based implants to optimize the treatment of brain disorders, such as Parkinson’s and epilepsy.
The cost of brain disorders in Europe alone reaches approximately € 800 billion a year, with more than a third of the population affected. More research needs to be done in this field, with new and more efficient diagnostic and therapeutic tools, and we seem to be on the right track.
INBRAIN Neuroelectronics was established in 2019 with the mission of developing brain implants based on graphene technology, something that we have already seen on several occasions at MWC. The goal is to treat patients with epilepsy, Parkinson’s and other neuronal diseases using smart devices, built around an innovative graphene electrode, that will decode with high-fidelity neuronal signals from the brain and produce a therapeutic response tailored to the specific patient’s clinical condition.
The idea is solidified with the investment of 1 million euros in a risk fund promoted and administered by IESE Business School. The new investment will allow INBRAIN to accelerate the development of these new intracranial implants for patients affected by brain disorders.
INBRAIN designs the least invasive and intelligent neural interface on the market that, driven by artificial intelligence and the use of Big Data, will have the ability to read and modulate brain activity, detect specific biomarkers and trigger adaptive responses to offer optimal results in personalized neurology therapies. .
So far it has already been used successfully to complete studies in small animals, and now they will do so with large animals in order to ensure that these graphene devices are safe and superior to current solutions based on metals, such as platinum and iridium. . The company also plans to begin human studies soon.
While graphene can already be found in many existing devices on the market (you can see our graphene category to verify it), we have not yet analyzed the entire tip of the iceberg, much less what is underneath.
